Genprex (GNPX) GPX-001 is now REQORSA
Good day everyone,
We are continuing our coverage of Genprex, Inc. (NASDAQ: GNPX), a clinical stage gene therapy company involved in developing various approaches to treating cancer, currently focused on non-small cell lung cancer (NSCLC), and autoimmune therapy currently focused on diabetes. GNPX has a proprietary technology platform designed to deliver tumor suppressor genes to cancer cells.
Current price $3.47 per share
In the first hour of trading on Thursday October 29th, GNPX shares are up 12.31% from yesterday’s close. Trading volume has already passed the daily average reflecting bullish sentiment.
Breaking News:
Genprex Receives Conditional FDA Acceptance of Proprietary Name REQORSA™ for Lead Drug Candidate for Treatment of Non-Small Cell Lung Cancer
“We are very pleased to receive FDA’s conditional acceptance of our proprietary name, REQORSA, which is a necessary step toward being able to market our lead drug candidate for non-small cell lung cancer,” said Rodney Varner, President and Chief Executive Officer of Genprex.
We’ve linked the full press release here
We can stop referencing GPX-001 (the GNPX TUSC2 tumor suppressor gene) and now refer to REQORSA.
The FDA will give the name a final review upon the completion of clinical milestones, but we believe the name will stick. GNPX is working with several big pharma companies using REQORSA in combination with their own products so the development of a name for GPX-001 may eliminate any confusion.
Further, any reporting about collaborative developments in clinical trials will now refer to the “Genprex drug REQORSA”.
The link below will take you to an FDA webpage (PDF file) containing information about the FDA process and reasons for naming drugs.
https://www.fda.gov/media/72409/download#:~:text=When%20reviewing%20a%20proposed%20proprietary,prescribing%2C%20dispensing%2C%20administering).
The Traders News Group
This week’s original report below
Genprex (GNPX) May be Ready for a Breakout
Good day everyone,
We are once again initiating coverage of Genprex, Inc. (NASDAQ: GNPX), a clinical stage gene therapy company involved in developing various approaches to treating cancer, currently focused on non-small cell lung cancer (NSCLC), and autoimmune therapy currently focused on diabetes. GNPX has a proprietary technology platform designed to deliver tumor suppressor genes to cancer cells.
Current price $3.09 per share
Outstanding shares (est.) 38.63M
Shares in Float (est.) 31.73M
Insider ownership 23%
Institutional ownership 12.82%
Considerations for GNPX shares:
The shares are trading 56% off their 52-week high
Insider and institutional ownership are high
The company has a very modest share structure
The chart setup looks ready for a breakout
We wanted to talk about GNPX shares again because they seem to be in a value range right now and poised for a breakout. GNPX shares have established a definable trading pattern in 2020 and would appear to currently be at their support level.
The 23% insider ownership is significant giving a vested interest to the management team. Twenty institutions hold GNPX shares, led by Blackrock, Inc. with 4.7% of the outstanding shares.
The active ingredient in their lead product candidate, GPX-001, is the TUSC2 gene, a tumor suppressor gene. The goal at GNPX is to find drugs from other companies that can work in combination with GPX-001 and be delivered with the GNPX proprietary Oncoprex nanoparticle delivery platform.
In January 2020, the FDA granted Fast Track Designation for GPX-001 in combination with AstraZeneca’s Tagrisso for the treatment of NSCLC. Tagrisso, with sales of more than $3 billion in 2019, is AstraZeneca’s largest selling drug.
Keytruda, with sales of more than $11 billion in 2019, is Merck’s largest selling drug. Data show that combining GPX-001 with Tagrisso or Keytruda achieves more favorable results than either drug alone.
The Oncoprex delivery system may be the product that takes GNPX to the next level. Oncoprex is a platform designed and optimized to deliver cancer-fighting genes into the patient’s body. These cancer-fighting genes are encapsulated in nanoscale hollow spheres called “nanoparticles,” which are then administered intravenously and taken up by tumor cells where they express proteins that are missing or found in low quantities.
Nanoparticles can carry therapeutic genes, whether they are a GNPX gene, another company’s gene or a combination thereof get delivered to a tumor via intravenous injection. That is, no doubt, a large part of why large pharma players are collaborating with GNPX.
GPX-002 is a gene therapy for both type 1 and type 2 diabetes that is in the pre-clinical stage. The goal of this therapy is to increase the production of insulin in the pancreas. A Phase I clinical trial could be the first-ever gene therapy tested in humans for diabetes.
We include a link below to an investor presentation created by Genprex that will give you all the clinical information about the company and its products: https://www.genprex.com/downloads/investor-presentation.pdf
Genprex has no debt and had $22M in cash as of June 30, 2020.
The company was added to the Russell 3000 Index on Friday, June 26, 2020.
5/26/2020 Noble Financial Buy $5.00
4/22/2020 Alliance Global Buy —–
As the chart linked below indicates, GNPX shares are trading below their 50 DMA of $3.65 and slightly above their 200 DMA of $$3.08/share. The current RSI (14) is 36.02. We believe GNPX shares may currently be at a price support level.
https://stockcharts.com/h-sc/ui?s=GNPX
About Genprex:
The company’s lead product candidate is GPX-001 (quaratusugene ozeplasmid) for non-small cell lung cancer (NSCLC). The active ingredient in GPX-001 is the TUSC2 gene, a tumor suppressor gene. GPX-001 uses the company’s unique, proprietary Oncoprex™ nanoparticle delivery platform which delivers cancer-fighting genes by encapsulating them into nanoscale hollow spheres called nanoparticles, which are then administered intravenously and taken up by tumor cells where they express proteins that are missing or found in low quantities. In January 2020, the FDA granted Fast Track Designation for GPX-001 in combination with AstraZeneca’s Tagrisso for the treatment of NSCLC. GPX-002, a gene therapy for diabetes, is the most recent addition of their licensed technologies.
Ofcourse, we have an updated report coming soon.
The Traders News Group
_____________________________________
Privacy Policy and Disclaimer
Your Consent
By using our site, you consent to our online privacy policy and disclaimer.
Do we disclose any information to outside parties?
We hate spam and we do not sell, trade, or otherwise transfer to outside parties your personally identifiable information.
What information do we collect?
We collect information from you when you subscribe to our newsletter or fill out a form. This includes your email address only.
When registering on our site, as appropriate, you may be asked to enter your: e-mail address
What do we use your information for?
When we collect your email it is used for one purpose to send you the free information you requested about small cap stocks. Please read our disclaimer carefully before viewing our emails.
Your information, whether public or private, will not be sold, exchanged, transferred, or given to any other company for any reason whatsoever, other than for the express purpose of delivering the information on small cap stocks that you requested.
We send periodic emails
The email address you provide may be used to send you information, respond to inquiries, and/or other requests or questions.
How do we protect your information?
We implement a variety of security measures to maintain the safety of your personal information when you enter, submit, your email address. We use a secure third party to send email to you.
Because we value your privacy we have taken the necessary precautions to be in compliance with the California Online Privacy Protection Act. We therefore will not distribute your personal information to outside parties without your consent.
Online Privacy Policy Only
This online privacy policy applies only to information collected through our website and not to information collected offline.
Contacting Us
If there are any questions regarding this privacy policy or disclaimer you may contact us using the information below.
Editor@TradersNewsSource.com
Traders News Source is a wholly owned subsidiary of Traders News Source LLC, herein referred to as TNS LLC.
Our reports/releases are a commercial advertisement and are for general information purposes ONLY. We are engaged in the business of marketing and advertising companies for monetary compensation. Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment. The disclaimer is to be read and fully understood before using our services, joining our site or our email/blog list as well as any social networking platforms we may use.
PLEASE NOTE WELL: TNS LLC and its employees are not a Registered Investment Advisor, Broker Dealer or a member of any association for other research providers in any jurisdiction whatsoever.
Release of Liability: Through use of this website viewing or using you agree to hold TNS LLC, its operators owners and employees harmless and to completely release them from any and all liability due to any and all loss (monetary or otherwise), damage (monetary or otherwise), or injury (monetary or otherwise) that you may incur. The information contained herein is based on sources which we believe to be reliable but is not guaranteed by us as being accurate and does not purport to be a complete statement or summary of the available data. TNS LLC encourages readers and investors to supplement the information in these reports with independent research and other professional advice. All information on featured companies is provided by the companies profiled, or is available from public sources and TNS LLC makes no representations, warranties or guarantees as to the accuracy or completeness of the disclosure by the profiled companies. None of the materials or advertisements herein constitute offers or solicitations to purchase or sell securities of the companies profiled herein and any decision to invest in any such company or other financial decisions should not be made based upon the information provide herein. Instead TNS LLC strongly urges you conduct a complete and independent investigation of the respective companies and consideration of all pertinent risks. Readers are advised to review SEC periodic reports: Forms 10-Q, 10K, Form 8-K, insider reports, Forms 3, 4, 5 Schedule 13D. TNS LLC is compliant with the Can Spam Act of 2003. TNS LLC does not offer such advice or analysis, and TNS LLC further urges you to consult your own independent tax, business, financial and investment advisors. Investing in micro-cap and growth securities is highly speculative and carries an extremely high degree of risk. It is possible that an investors investment may be lost or impaired due to the speculative nature of the companies profiled.
The Private Securities Litigation Reform Act of 1995 provides investors a safe harbor in regard to forward-looking statements. Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, goals, assumptions or future events or performance are not statements of historical fact may be forward looking statements. Forward looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements in this action may be identified through use of words such as projects, foresee, expects, will, anticipates, estimates, believes, understands, or that by statements indicating certain actions & quote; may, could, or might occur. Understand there is no guarantee past performance will be indicative of future results.
In preparing this publication, TNS LLC has relied upon information supplied by its customers, publicly available information and press releases which it believes to be reliable; however, such reliability cannot be guaranteed. Investors should not rely on the information contained in this website. Rather, investors should use the information contained in this website as a starting point for doing additional independent research on the featured companies. TNS LLC’s parent company has been compensated sixteen thousand five hundred dollars cash via bank wire by legends media llc for this weeks coverage of gnpx.The advertisements in this website are believed to be reliable, however, TNS LLC and its owners, affiliates, subsidiaries, officers, directors, representatives and agents disclaim any liability as to the completeness or accuracy of the information contained in any advertisement and for any omissions of materials facts from such advertisement. TNS LLC is not responsible for any claims made by the companies advertised herein, nor is TNS LLC responsible for any other promotional firm, its program or its structure.
TNS LLC is not affiliated with any exchange, electronic quotation system, the Securities Exchange Commission or FINRA. TNS LLC is not a Broker/Dealer and does not engage in high frequency trading.
